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Despite signiﬁcant progress in the treatment of preterm neonates, bronchopulmonary dysplasia (BPD) continues to be a major
cause of neonatal morbidity. Aﬀected infants suﬀered from long-term pulmonary and nonpulmonary sequel. The pulmonary
sequels include reactive airway disease and asthma during childhood and adolescence. Nonpulmonary sequels include poor
coordination and muscle tone, diﬃculty in walking, vision and hearing problems, delayed cognitive development, and poor
academic achievement. As inﬂammation seems to be a primary mediator of injury in pathogenesis of BPD, role of steroids as
antiinﬂammatoryagenthasbeenextensivelystudiedandproventobeeﬃcaciousinmanagement.However,evidenceisinsuﬃcient
to make a recommendation regarding other glucocorticoid doses and preparations. Numerous studies have been performed to
investigate the eﬀects of steroid. The purpose of this paper is to evaluate these studies in order to elucidate the beneﬁcial and
harmful eﬀects of steroid on the prevention and treatment of BPD.
1.Introduction
Despite signiﬁcant progress in the treatment of preterm
neonates, bronchopulmonary dysplasia (BPD) continues to
be a major cause of neonatal morbidity. At earlier times,
it was considered to be primarily iatrogenic in etiology as
a consequence of crude ventilator techniques. In current
time with advanced and sophisticated ventilator techniques,
BPD continued to be a major sequel of neonatal respir-
atory distress syndrome (RDS), primarily because of better
survival of extreme premature babies with other factors
including ventilator-induced lung injury, exposure to oxy-
gen, and inﬂammation. New bronchopulmonary dysplasia
(new BPD) is characterized, in part, by arrested alveolar and
vascular development of the immature lung [1]. Aﬀected
infants suﬀer from long-term pulmonary and nonpulmo-
nary sequel. The pulmonary sequels include reactive airway
disease and asthma during childhood and adolescence [2, 3].
Nonpulmonary long-term sequels include poor coordina-
tion and muscle tone, diﬃculty in walking, vision and hear-
ing problems, delayed cognitive development, and poor ac-
ademic achievement [4].
The proposed etiology of new BPD is the initiation of
inﬂammatory mediators that cause impairment of alveola-
rization and vasculogenesis [5]. The lacking anti-inﬂamma-
tory mediators in the preterm neonate may be inundated
easily by the proinﬂammatory cascade. A diﬀerence in the
release of pro- and anti-inﬂammatory cytokines, occurring
as a result of intrauterine/postnatal infection (sepsis), venti-
latortrauma,oxidants,pulmonaryedema,orsepsis,damages
the immature lung.
As inﬂammation seems to be primary mediator of in-
jury in pathogenesis of BPD, role of steroids as anti-inﬂam-
matory agent has been extensively studied and proven
to be eﬃcacious in management. But studies in last one
and half decade have seriously questioned the routine use2 International Journal of Pediatrics
of steroids especially high-dose dexamethasone due to its
long-term eﬀect on neurodevelopment. In 2010, the Amer-
ican Academy of Pediatrics (AAP) revised policy statement
regarding the use of postnatal corticosteroids for prevention
or treatment of chronic lung disease in preterm infants,
concluded that high-dose dexamethasone (0.5mg/kg/day)
does not seem to confer additional therapeutic beneﬁt
over lower doses, and is not recommended. Evidence is
insuﬃcient to make a recommendation regarding other
glucocorticoid doses and preparations. The clinician must
use clinical judgment when attempting to balance the
potential adverse eﬀects of glucocorticoid treatment with
those of BPD. Postnatal use of dexamethasone for BPD has
decreased since the publication of the AAP statement in
2002; however, the incidence of BPD has not decreased [6].
Instead, several reports have suggested that the incidence or
severity of BPD may have increased. Despite AAP statement
to limit the use of systemic dexamethasone especially high
dose, seems reasonable considering it has proven adverse
eﬀect on neurodevelopment. But that cannot negate the
fact that steroids do have beneﬁcial eﬀects on pulmonary
physiology, and currently we do not have any other anti-
inﬂammatory of similar eﬃcacy. If we can limit the systemic
side eﬀects of steroid in some way and can utilize its local
anti-inﬂammatory eﬀect on lung, it can be a very useful drug
in management of new BPD.
Various mechanisms have been described for beneﬁcial
eﬀect of steroids on lung mechanics in infants with BPD.
Various steroids of diﬀerent potency have been studied
at various timings; in diﬀerent dosing regimens; for dif-
ferent duration; in diﬀerent forms (including intravenous,
inhalational, intratracheal, and recently intratracheal with
surfactant as a vehicle). Amongst systemically used steroids,
dexamethasone comes as the most potent and most studied
o n e .I th a sb e e ns t u d i e di ne a r l y( <7 days), moderately
early (7–14 days) and late/delayed (>14 days), postna-
tal periods and dosing ranging from 0.1mg/kg/day to
0.5mg/kg/day and duration ranging from 3 days to 42
days. Hydrocortisone comes second. Beclomethasone is the
most commonly used inhalational steroid for BPD. Recently,
budesonide has been tried as intratracheal instillation with
or without surfactant as a vehicle and shown to reduce
inﬂammatory marker in tracheal aspirates in initial clinical
trials.
2. Possible Mechanismsof Action
of Glucocorticoids
AsthepathogenesisofBPDismultifactorial,soarethemech-
anisms to respond to steroid therapy. Since inﬂammation
seems to play a critical role in the evolution of BPD, beneﬁt
seen with glucocorticoids most likely mediates through its
anti-inﬂammatory eﬀect.
The primary anti-inﬂammatory eﬀect of glucocorticoids
is mediated by annexin-1 synthesis. Annexin-1 suppresses
phospholipase A2 expression, thereby blocking eicosanoids
(i.e., prostaglandins, thromboxanes, prostacyclins, and leu-
kotrienes) and the subsequent leukocyte inﬂammatory
events including adhesion and migration. Thus, glucocor-
ticoids inhibit two main products of inﬂammation pros-
taglandinsandleukotrienes.Inaddition,glucocorticoidsalso
suppress both cyclooxygenase I and II similar to NSAID,
potentiating the anti-inﬂammatory eﬀect [7].
Lung inﬂammation is downregulated by dexamethasone
therapy. Groneck et al. evaluated the tracheobronchial
aspirate from preterm infants at high risk of BPD. The
numberofneutrophilsandconcentrationsofleukotrieneB4,
interleukin-1, elastase-α1-protease inhibitor, and albumin
were decreased after dexamethasone treatment [8]. It indi-
cates that dexamethasone aﬀects the release of inﬂammatory
mediators and neutrophils inﬂux into the airways of preterm
infants who require mechanical ventilation and decreases
the microvascular permeability. Pulmonary edema is the
hallmark of BPD; dexamethasone has been shown to reduce
the pulmonary edema in infants with BPD.
Glucocorticoids block the release of arachidonic acids
and its subsequent conversion to eicosanoids. The decreased
incidence of patent ductus arteriosus (PDA) after pre-
natal or postnatal steroid therapy is likely due to the
inﬂuence of the corticosteroid eﬀect on the responsive-
ness of ductal tissue to prostaglandins. Prostaglandin has
an important role in maintaining the integrity of gas-
trointestinal mucosa. The use of steroids may increase
the risk of gastrointestinal perforation. Other mechanisms
such as modulating the transcription and posttranscrip-
tional regulation of surfactant component, stimulation of
antioxidant production, and enhancement of adrenergic
activities may also be responsible for the acute and rapid
improvement of pulmonary function [9]. Unfortunately,
some of these mechanisms are also involved in physi-
ologic signaling other than inﬂammatory signaling; the
therapeutic eﬀects of glucocorticoids in inﬂammation are
often accompanied by clinically signiﬁcant side eﬀects.
Glucocorticoid receptors are present virtually in all cells.
Prolonged or high-dose glucocorticoids therapy causes
multiple systemic side eﬀects. There is a consensus that
the desired anti-inﬂammatory eﬀects of glucocorticoids
are mainly mediated via repression of gene transcription.
In contrast, the underlying molecular mechanisms for
glucocorticoids-mediated side eﬀects are complex and partly
understood.
3. Postnatal Corticosteroid Therapy in
Preterm Infants
3.1. Choice of Glucocorticoids. Dexamethasone is a potent,
long-acting steroid with exclusive glucocorticoid eﬀect.
When compared to hydrocortisone, dexamethasone is 25–50
times more potent. The half-life is 36–54 hours. Dexametha-
sone has been extensively studied in neonatal medicine and
hasshowntoimprove pulmonary function, facilitateextuba-
tion, and decrease the incidence of BPD [10–15]. However,
many associated adverse side eﬀects prevent the routine
use of dexamethasone. The short-term side eﬀects include
hyperglycemia, hypertension, hypertrophic cardiomyopa-
thy, gastrointestinal bleeding, and perforation. The riskInternational Journal of Pediatrics 3
of gastrointestinal perforation increases with concomitant
indomethacin treatment [16]. There is also a concern
with the chronic suppression of the hypothalamic-pituitary-
adrenal axis [17, 18] and long-term neurodevelopmental
delay [19, 20].
On the other hand, hydrocortisone has almost equal
glucocorticoid and mineralocorticoid action, and the half-
life is only 8 hours. Sick premature infants have relative
adrenal insuﬃciency during acute illness because of devel-
opmental immaturity of the hypothalamic-pituitary-adrenal
axis suggesting that an early physiological replacement of
cortisol may be needed [21–24]. However, large doses above
physiologic levels to achieve the anti-inﬂammatory action
may cause signiﬁcant mineralocorticoid side eﬀects. Early
useofhydrocortisone (<48hours)wasshowntodecreasethe
risk of PDA but increased survival only in infants exposed to
maternal chorioamnionitis or who had low cortisol values
[22, 23].
Another steroid betamethasone, a stereoisomer of dex-
amethasone, diﬀers only in the orientation of the methyl
group at position 16. However, this structural diﬀerence
could be responsible for marked diﬀerences in nongenomic
eﬀects. Previous antenatal steroid studies have demonstrated
that both drugs have the same eﬀects in reducing the
risk of intraventricular hemorrhage, but betamethasone has
been shown to be more eﬀective than dexamethasone in
reducing the risk of neonatal death and cystic periventricular
leukomalacia among very premature infants [24, 32]. The
study of betamethasone in postnatal use is limited. A
recent study has shown that betamethasone is as eﬀective
as dexamethasone in improving pulmonary function, but
with fewer adverse eﬀects, such as poor weight gain and
hyperglycemia [33].
Inhaledglucocorticoidshavebeenusedinneonateswith-
out concomitant systemic side eﬀects. They have been suc-
cessfully used for years in asthmatic patients, but their eﬀects
on mechanical ventilated preterm infants are less impressive.
The delivery of inhaled glucocorticoids in preterm infants
is technically diﬃcult, and its eﬀectiveness has been shown
to be limited. Similarly, direct intratracheal instillation of
glucocorticoidsalonehasalsonotbeenshowntobeeﬀective.
A topical glucocorticoid aerosol (budesonide, ﬂuticasone, or
beclomethasone) is administered by metered dose inhaler
and spacer directly to the endotracheal tube of intubated
infants. In an animal model, delivery of beclomethasone to
the lungs of an intubated neonate was only 1-2% of the
original aerosolized drug [34]. The inhaled steroid did not
decrease the incidence of BPD but improved blood gas, chest
X-ray score, and a decrease in the use of systemic steroids
[35–38].
ArecentstudyfromYehetal.suggestedthatintratracheal
instillation of budesonide, a strong local glucocorticoids,
using surfactant as vehicle may eﬀectively deliver the med-
ication to the lung and may decrease the incidence of BPD
[39].
3.2. Timing of Postnatal Steroid Use. The potential mecha-
nism of glucocorticoids in premature infants with RDS is not
exactly known. Most of the clinical trials only evaluated clin-
ical responses and did not study mechanisms explaining the
beneﬁcial eﬀects. Based on the pathologic and physiologic
studies, it seems that steroid therapy given at diﬀerent times
may mediate physiologic eﬀect via diﬀerent mechanisms.
Premature infants may develop lung injury shortly after
birth and during the ﬁrst 1-2 weeks after exposure to
infection, oxygen, or positive pressure ventilation. Therefore,
steroid should be given shortly after birth or during the
ﬁrst few weeks to prevent BPD via its anti-inﬂammatory
action. On the other hand, steroid therapy given at 3–6
weeks of life may derive its beneﬁts from the modulation
of lung repair. Alternately, steroids given at any age may be
eﬀective in infants with BPD by blunting hyperreactivity and
inﬂammation.
3.3. Dosage and Duration of Corticosteroids. Most recent
studies used a dose of dexamethasone 0.1–0.5mg/kg/day,
equivalent to 10 to 20 times of endogenous corticosteroid
levels, in durations ranging from 3 to 42 days. The high
dosage and long duration of treatment might be responsible
for the delay of brain growth and subsequent poor neurode-
velopmental outcomes. A lower dose and shorter duration
of dexamethasone may be beneﬁcial and without signiﬁcant
side eﬀects. However, the proper dosage and duration of
treatment has not been well deﬁned.
Compare to dexamethasone, the dosage of hydrocorti-
sone used in the trials aimed to prevent BPD was smaller,
ranging from 1-2mg/kg/day, which is equivalent to 1 to 2
times the physiological level. Unfortunately, the low-dose
replacement showed no reduction of BPD.
4. CurrentEvidence of Steroid Use:
AAP RevisedPolicy,2010
4.1. Dexamethasone. Current evidence suggests that dexam-
ethasone may decrease mortality rates, facilitate extubation,
and generally decrease the incidence of BPD but that it
carries a signiﬁcant risk for short- and long-term adverse
eﬀects, especially impairment of growth and neurodevelop-
ment [6, 53–56].
(1) Cochrane database systemic review concluded that
the beneﬁts of dexamethasone therapy in the ﬁrst
weekoflifemaynotoutweighitsmanyadverseeﬀects
[57]. In contrast, it concludes that treatment after
the ﬁrst postnatal week may reduce mortality rates
without increasing adverse long-term neurodevelop-
mental outcomes although long-term follow-up data
remain limited [58].
(2) Two other systemic meta-analyses have been done
recently. In the ﬁrst review, a risk-weighted meta-
analysis, the authors emphasized the importance
of the a priori risk of death or BPD in diﬀerent
study populations [59]. In this analysis, the inci-
dence of death or cerebral palsy (CP) was increased
among dexamethasone-treated infants compared
with placebo-treated infants in studies that enrolled
patients at low risk (<35%) of BPD. In contrast,4 International Journal of Pediatrics
Table 1: RCTs of dexamethasone to prevent or treat BPD reported since 2001.
Study, no. of
centers n
Eligibility criteria
(all on mechanical
ventilation)
Timing Dexamethasone dosing
regimen Outcome
McEvoy et al.
[25], 1 center 62 500–1500g BW;
≤32wk gestation 7–21 postnatal days
5mg/kg/daytaperedover7
days versus 0.2mg/kg tapered
over 7 days
Rate of survival without BPD
76% versus 73% (NS); no
beneﬁt to higher dose
Odd et al.
[26], 1 center 33 ≤1250g BW 1–3 wk of age
0.5mg/kg/day tapered over 42
days versus “individualize”
(same dose, shorter course)
Rate of survival without BPD:
24% versus 30% (NS); no
diﬀerence in 18-month
outcomes
Malloy et al.
[27], 1 center 16 <1501g BW;
<34wk gestation <28 postnatal days
0.5mg/kg/day tapered over 7
days versus 0.08mg/kg/day for
7d a y s
Rate of survival without BPD:
11% versus 38% (NS); higher
dose had more adverse eﬀects,
no apparent beneﬁt
Walther et al.
[28], 1 center 36
≥600g BW;
24–32wk gestation 7–14 d postnatal age 0.2mg/kg/day tapered over 14
days versus placebo
Rate of survival without BPD:
65% versus 47% (NS);
extubation: 76% versus 42%
(P<. 05)
Anttila et al.
[29], 6
centers
109 500–999g BW;
≤31wk gestation Eligible at 4 h of age 0.25mg/kg every 12h × 4
d o s e sv e r s u sp l a c e b o
Rate of survival without BPD:
58% versus 52% (NS)
Doyle et al.
[30], 11
centers
70 <1000g BW;
<28wk gestation >1wk postnatal age 0.25mg/kg every 12h × 4
d o s e sv e r s u sp l a c e b o
Rate of survival without BPD:
14% versus 9% (NS);
extubation: 60% versus 12%
(odds ratio: 11.2 (95%
conﬁdence interval: 3.2–39.0))
Rozycki et al.
[31], 1 center 61 650–2000g BW ≥14 day postnatal age
0.5mg/kg/day tapered over 42
day versus inhaled
beclomethasone at 3 diﬀerent
d o s e sf o r7d a y sf o l l o w e db y
the above-listed
dexamethasone course, if still
mechanically ventilated
Rate of survival without BPD:
53% versus 46% (NS);
extubation by 7d: 7 of 15
versus 6 of 46 (P<. 01)
BW = body weight; NS = not signiﬁcant.
dexamethasone treatment decreased the risk of death
or CP when infants at high risk of BPD (≥65%)
were studied [59]. Thus, for infants at the highest
risk of BPD, the beneﬁcial eﬀect of dexamethasone in
reducing lung disease seemed to outweigh its adverse
eﬀect of increasing the risk of CP. In the second
meta-analysis, the authors compared outcomes for
trials with diﬀerent cumulative doses of dexametha-
sone and concluded that a higher cumulative dose
improved rates of survival without BPD and did not
increase adverse long-term eﬀects [60].
(3) Small individual randomized controlled trials
(RCTs) that directly compared high-versus low-
dexamethasonedoses, variablydeﬁned, haverevealed
no diﬀerences in eﬃcacy (Table 1)[ 25–27]. These
studies have generally been small and heterogeneous,
which makes them diﬃcult to compare.
(4) Three RCTs have compared dexamethasone to
placebo (Table 1); 1 was small and the other 2 were
stopped early and are, therefore, underpowered [28–
30]. One trial compared an early, short course of
dexamethasone to placebo and revealed no signiﬁ-
cant diﬀerence in mortality or BPD rates [29]. The
other 2 trials evaluated the eﬃcacy of a later, lower-
dose course of dexamethasone for facilitating extu-
bation, and the authors reported that signiﬁcantly
more dexamethasone-treated infants were success-
fully extubated during the treatment period [28, 30].
Similar results were reported from an additional
study that compared systemic dexamethasone to
inhaled beclomethasone for extubation; signiﬁcantly
more dexamethasone-treated infants were success-
fully extubated within 7 days (Table 1)[ 31]. These
extubation trials were not powered to evaluate the
eﬀect of the treatment on rates of survival without
BPD.
(5) Many short-term adverse eﬀects of dexamethasone
therapy have been described; however, the main
reason for the decline in its use is an adverse eﬀect on
neurodevelopment, particularly higher rates of CP.
Eleven RCTs have been done to evaluate long term
neurodevelopmental outcome (Table 2)[ 25, 40–48].International Journal of Pediatrics 5
Table 2: Neurodevelopmental follow-up of dexamethasone RCTs reported after 2001.
Study, planned
age at followup
Followup, % (no.
of infants seen) Treatment start time Dexamethasone dosing regimen Primary neurodevelopmental
ﬁndings
McEvoy et al.
[25], 1 year 66 (39) At 7–21 days
High versus low dose: 7-day
taper from 0.5mg/kg/day versus
0.2mg/kg/day
MDI < 70: 24% (high) versus
17% (low) (NS);
CP: 10% versus 11% (NS)
Armstrong et al.
[40], 18 months
chronological
age
96 (64) On day 7 42-d taper versus 3-day pulse
No diﬀerence in 18-month
outcomes
No disability: 34% versus 31%
(NS)
Doyle et al. [41],
2 years
corrected age
98 (58) After 7 days 0.15mg/kg/day tapered over 10
days
Death or major disability: 46%
versus 43% (NS); death or CP:
23% versus 37% (NS); CP: 14%
versus 22% (NS); major
disability 41% versus 31% (NS)
Stark et al. [42],
18–22 months
corrected age
74 (123) On day 1 0.15mg/kg/day tapered over 7
days
MDI < 70: 51% versus 43%
(NS); PDI < 70: 30% versus 35%
(NS); abnormal neurologic
exam: 25% each group
Romagnoli et al.
[43], 3 years 100 (30) On day 4 0.5 mg/kg/day tapered over 1 wk No diﬀerences in any parameter;
CP: 9% versus 14% (NS)
Wilson et al.
[44], 7 years 84 (127) Before 3 days
4 groups: 0.5mg/kg/day tapered
over 12 days versus late (15 days)
selective, versus inhaled early or
late selective
No diﬀerence in cognitive,
behavioral, CP, or combined
outcomes
Yeh et al. [45],
school age
(mean: 8 years)
92 (146) On day 1 0.5mg/kg/day for 1 wk, then
tapered for a total of 28 days
Treated children were shorter
(P = .03), had smaller head
circumference (P = .04), lower
IQ scores (P = .008), and more
signiﬁcant disabilities (CP, IQ <
5th percentile, vision or hearing
impairment): 39% versus 22%
(P = .04)
O’Shea et al.
[46], 4–11 years 89 (84) On day 15–25 0.5mg/kg/day tapered over 42
days versus placebo
Death or major NDI: 47% versus
41% (NS); major NDI alone:
36% versus 14% (P =.01)
Gross et al. [47],
15 years 100 (22) On day 14
0.5mg/kg/day tapered over 42
days versus 18-day taper versus
placebo
Intact survival (IQ > 70, normal
neurologic exam, regular
classroom): 69% versus 25%
(18-d course) versus 18%
(placebo) (P<. 05)
Jones and the
Collaborative
Dexamethasone
Trial Follow-up
Group [48],
13–17 years
95 (150) At 2–12 wk 0.5mg/kg/day for 7 days
No diﬀerence in moderate/severe
disability (deﬁned as IQ > 2S D s
< mean, CP, hearing or vision
loss); CP: 24% versus 15%
(relative risk: 1.58 [95%
conﬁdence interval: 0.81–3.07])
NDI: neurodevelopmental impairment; PDI: psychomotor developmental index; NS: not signiﬁcant.
The heterogeneity of these reports makes it prob-
lematic to combine them meaningfully. Some studies
did not reveal adverse eﬀects on neurodevelopmental
outcomes at various ages, whereas others did. Most
of the studies were small, which reduced their ability
to either prove or disprove causation. Two RCTs that
used low doses of dexamethasone revealed no sig-
niﬁcant increase in CP or other neurodevelopmental
impairments when compared with placebo. Because
only a total of 96 dexamethasone-treated infants
were evaluated in these studies, the results must be
interpreted with caution [41, 42].
(6) Cohort studies of dexamethasone have revealed an
association of its use with impaired neurodevelop-
mental outcomes [48, 61]; however, such an asso-
ciation cannot be construed as deﬁnitive evidence
of harm. A clinician’s decision to use a therapy6 International Journal of Pediatrics
incorporates numerous undocumented factors and
varies from one clinician to the next, which may
seriouslyconfoundtheinterpretationofsuchstudies.
Patients who receive dexamethasone for BPD are
likely to be perceived as having more severe respira-
tory disease than infants who are not treated; such
infants may have worse overall outcomes regardless
of dexamethasone therapy.
(7) Authorsof small series have alsoreported that infants
treatedwithdexamethasonehavemoreabnormalities
on MRI than those not treated; again, causation
cannot be attributed in the absence of an RCT [61,
62]. Two previously reported RCTs revealed more
cranial ultrasound abnormalities in dexamethasone-
treated infants compared with those treated with
placebo, but the patient numbers were quite small
[63, 64].
In summary, high daily doses of dexamethasone have
been linked frequently to adverse neurodevelopmental out-
comes, and this therapy is discouraged. Because an increase
in adverse neurodevelopmental outcomes in treatment stud-
ies that used low doses of dexamethasone has not been
reported, further studies of low-dose dexamethasone to
facilitate extubation are warranted.
4.2. Hydrocortisone.
(1) Four RCTs designed to evaluate the ability of early
hydrocortisone therapy to improve rates of sur-
vival without BPD have been done in recent times
(Table 3)[ 49–52] .T h e s es t u d i e sw e r eb a s e do nt h e
premise that extremely preterm infants may have
immature adrenal gland function, predisposing them
to a relative adrenal insuﬃciency and inadequate
anti-inﬂammatory capability during the ﬁrst several
w e e k so fl i f e[ 21, 65–68]. In contrast to the het-
erogeneous nature of previous dexamethasone trials,
thesestudiesweresimilarindesign,timeofinitiation,
duration,anddose.Thedirectionofeﬀectfavoredthe
hydrocortisone-treated infants in all 4 studies, and a
signiﬁcant increase in rate of survival without BPD
in the hydrocortisone-treated infants was reported
for 2 of the studies. The largest trial (n = 360)
did not reveal a signiﬁcant beneﬁt of hydrocortisone
treatment in the overall study group; however, for
infants exposed to prenatal inﬂammation (n = 149),
identiﬁedbeforethetrialasaspeciﬁcgroupforanaly-
sis, hydrocortisone treatment resulted in a signiﬁcant
decrease in mortality rate and an increase in rate
of survival without BPD [50]. Patient enrollment
was halted early in 3 of these 4 studies because of
a signiﬁcant increase in spontaneous gastrointestinal
perforationdiscoveredinthelargesttrial[50],ac om-
plication also observed with early dexamethasone
[68, 69]. The perforations may have resulted from
an interaction between high endogenous cortisol
concentrations and indomethacin therapy in the
ﬁrst 48 hours; however, because administration of
indomethacin was not randomized, this hypothesis
remains to be tested.
(2) Neurodevelopmental outcomes at 18 to 22 months’
correctedagehavebeenpublishedfor3ofthesetrials,
and no adverse eﬀects of hydrocortisone treatment
were found [70, 71]. In the largest multicenter
trial, the incidence of death or major neurodevelop-
mental impairment (52% (hydrocortisone-treated)
versus 56% (placebo)), major neurodevelopmental
impairment alone (39% versus 44%), and CP (16%
versus 18%) was similar [70]. The only signiﬁcant
ﬁndings favored the hydrocortisone-treated group
and included a decreased incidence of a Bayley
Scales of Infant Development (2nd edition) Mental
Developmental Index (MDI) 2 SDs below the mean
(MDI < 70, 27% versus 37%; odds ratio: 0.47 (95%
conﬁdence interval: 0.25–0.87)) and a higher inci-
dence of awareness of object permanence (an early
test of working memory and prefrontal executive
function) (89% versus 79%; odds ratio: 2.19 (95%
conﬁdence interval: 1.06–4.52)).
(3) Hydrocortisone therapy given to facilitate extubation
has been studied in cohort studies. In the ﬁrst
reported study, 25 infants treated with hydrocorti-
sone at 1 hospital (5mg/kg per day, tapered over 3
weeks) were compared with 25 untreated infants at
thesamehospitalandadditionallywithacohortof23
infants treated with dexamethasone (0.5mg/kg per
day, tapered over 3 weeks) at a separate hospital [72].
The investigators found that hydrocortisone was as
eﬀective as dexamethasone in weaning infants from
the ventilator and in decreasing supplemental oxygen
therapy, with fewer short-term adverse eﬀects. Fol-
lowup of these children at school age revealed no dif-
ferences in neurodevelopmental outcomes between
hydrocortisone-treated infants and their comparison
group, whereas dexamethasone-treated infants more
often had an abnormal neurologic examination and
less favorable school performance than their com-
parison cohort [72–75]. Subsequently, several large
cohort studies from the same institution reported
that although hydrocortisone-treated children were
younger, smaller, and sicker than their untreated
comparison groups, there were no adverse eﬀects
of hydrocortisone treatment on IQ, visual motor
integration, memory testing, CP, or ﬁndings on
MRI [74–76]. Investigators from this institution
have also reported that neonatal dexamethasone but
not hydrocortisone therapy resulted in long-lasting
changes in hypothalamic-pituitary-adrenal axis and
T-cell function [77].
4.3. Diﬀerences between Dexamethasone and Hydrocortisone.
As discussed before, many RCTs have shown adverse neu-
rodevelopmental outcomes after postnatal dexamethasone
treatment for BPD, but neither multicenter RCTs nor cohortInternational Journal of Pediatrics 7
Table 3: RCTs of early hydrocortisone to prevent BPD.
Study, no. of
centers n Population: mechanically
ventilated infants Timing Hydrocortisone
dosing regimen
Rate of survival
without BPD HC
versus placebo, %
Watterberg et al.
[49], 2 centers 40 BW: 500–999g <48h postnatal age
0.5mg/kg every 12h
for 9 days
0.25mg/kg every 12h
for 3 days
60 versus 35 (P = .04)
Watterberg et al.
[50], 9 centers 360 BW: 500–999g <48h postnatal age
0.5mg/kg every 12h
for 12 days
0.25mg/kg every 12h
for 3 days
35 versus 34 (OR: 1.20
(95% CI: 0.72–1.99))
Peltoniemi et al.
[51], 3 centers 51 BW: 501–1250g <36h postnatal age
2.0mg/kg/day tapered
to0.75mg/kg/day over
10 days
64 versus 46 (OR: 1.48
(95% CI: 0.49–4.48))
Bonsante et al.
[52], 2 centers 50 BW: 500–1249g <48h postnatal age
0.5mg/kg every 12h
for 9 days;
0.25mg/kg every 12h
for 3 days
64 versus 32 (P<. 05)
studies have revealed adverse eﬀects on functional or struc-
tural neurologic outcomes after neonatal hydrocortisone
therapy. Possible reasons could be as follows.
(1) Dissimilareﬀectiveglucocorticoiddose-neonatalani-
mal studies have consistently revealed adverse eﬀects
on brain growth after high doses of glucocorticoid
[78, 79], and results of evaluation of 22 patients
who received high-dose hydrocortisone in a study
from the early 1970s were suggestive of harm
[80, 81]. High-dose dexamethasone (0.5mg/kg per
day) is equivalent to at least 15 to 20mg/kg per
day of hydrocortisone [82], far higher than the
doses of hydrocortisone given in the recent studies
describedpreviously.Low-dosedexamethasone(0.1–
0.15mg/kg per day) may be equivalent to 3 to
6mg/kg per day of hydrocortisone; however, because
of its much longer biological half-life, it could have a
muchhigherrelativepotency[83].Loweringthedose
ofdexamethasonemay,therefore,decreaseitsadverse
eﬀects, as is suggested by the 2 studies of outcome
after lower-dose dexamethasone therapy [41, 42].
(2) There are dissimilar eﬀects of these agents on the
hippocampus, an area of the brain critical to learn-
ing, memory, and spatial processing [84, 85]. The
hippocampus contains a high density of both min-
eralocorticoid and glucocorticoid receptors [86, 87].
Hydrocortisone, which is identical to native cortisol,
canbindtobothclassesofreceptors.Incontrast,dex-
amethasone binds only to glucocorticoid receptors,
which, in animal models, has been shown to result in
degeneration and necrosis of hippocampal neurons
[88, 89]. This eﬀect of dexamethasone is blocked
by simultaneous administration of corticosterone
(the cortisol equivalent in the rat) [88]. In humans,
neonatal treatment with dexamethasone, but not
hydrocortisone,hasbeenshowntoalterhippocampal
synapticplasticityandassociativememoryformation
in later life [90]. Dexamethasone exposure has also
been linked to decreased hippocampal volume in
1c o h o r ts t u d y[ 91, 92], but cohort studies of
infants treated with hydrocortisone have revealed no
decrease in hippocampal volume [74], no adverse
eﬀect on hippocampal metabolism, and no adverse
eﬀect on memory at school age [76] when compared
with a larger, more mature group of nontreated
infants.
Whatever the underlying explanation(s) for the observed
diﬀerences in short- and long-term outcomes may be,
further RCTs are needed to answer the many remaining
questions, including whether lower doses of dexamethasone
can avoid previously observed adverse eﬀects, whether hy-
drocortisone is eﬃcacious for extubation, whether specif-
ic groups of infants may derive particular beneﬁt from hy-
drocortisone therapy, and whether the incidence of sponta-
neous gastrointestinal perforation during early glucocorti-
coid administration can be decreased by avoiding concom-
itant indomethacin or ibuprofen therapy and/or by monitor-
ing cortisol concentrations.
4.4. Other Glucocorticoids (Systemic). No available evidence
support use of other systemic glucocorticoids, such as
prednisone or methylprednisolone, to treat or prevent BPD.
4.5. Inhaled Glucocorticoids. Although some tertiary care
Neonatal ICUs routinely use inhaled beclomethasone for
BPD babies, no available evidence support the eﬃcacy of
inhaled glucocorticoids to prevent or decrease the severity of
BPD. Recent Cochrane database systemic review concluded
“there is no evidence that inhaling steroids prevent chronic
lungdiseaseorthenumberofdaysthebabyneededbreathing
support and additional oxygen” [93, 94].
Beclomethasone and ﬂunisolide have been studied by
nebulization in view of decreasing need for systemic steroid
and side eﬀects. The early postnatal administration of8 International Journal of Pediatrics
inhaled steroid to prevent BPD was studied in a large
randomized, multicenter trial [34]. In this study, 253 infants
with a gestation age of <33 weeks, a birth weight of <1250g,
and who were mechanically ventilated at 3 to 14 days of
age were randomly assigned to inhaled beclomethasone
or a placebo for four weeks. The need for supplemental
oxygen was similar in the beclomethasone and placebo
groups at 28 days of life and 36 weeks postmenstrual
age. In this study, beclomethasone therapy did not prevent
BPD; however, it signiﬁcantly reduced the use of systemic
glucocorticoid therapy and mechanical ventilation at 28 days
of age. In a small study, ﬂuticasone propionate inhalation
was given for 3 weeks to premature infants (less than 32
weeks) with moderate BPD (required fraction of inspired
oxygen >0.25 or mechanical ventilation) at 28–60 days.
There was no diﬀerence between infants treated with inhaled
ﬂuticasone versus placebo in the duration of oxygen therapy
or ventilatory support [32].
4.6. Direct Intratracheal Instillation (IT) of Steroid with or
without Surfactant as a Vehicle. Aerosolized drugs may be
ineﬀective in preterm infants as very little drug is delivered
to the lung, thereby limiting its eﬀects. Novel idea of using
surfactant as a vehicle to administer budesonide has been
under study. A recent study by Halliday et al. demonstrated
that intratracheal instillation of budesonide using surfactant
as a vehicle signiﬁcantly decreased the combined outcome
of death and CLD without apparent immediate and long-
term adverse eﬀects [56]. Budesonide is a strong topical anti-
inﬂammatory glucocorticoid. It can be eﬀectively delivered
to the lungs and remain in the lungs for some time after
intratracheal instillation. Once absorbed, it can be rapidly
metabolized to metabolites of low glucocorticoid eﬀect.
However, before this regimen can be recommended, a large
sample trial is needed.
5. Current Evidence-Based Recommendations
(AAP RevisedPolicyStatement, 2010)
(1) High daily doses of dexamethasone (approximately
0.5mg/kg per day) have been shown to reduce the
incidence of BPD but have been associated with
numerous short- and long-term adverse outcomes,
including neurodevelopmental impairment, and at
present, there is no basis for postulating that high
daily doses confer additional therapeutic beneﬁt over
lower-dose therapy.
Recommendation. In the absence of randomized
trial results showing improved short- and long-term
outcomes, therapy with high-dose dexamethasone
cannot be recommended.
(2) Low-dose dexamethasone therapy (<0.2mg/kg per
day) may facilitate extubation and may decrease the
incidence of short- and long-term adverse eﬀects
observed with higher doses of dexamethasone. Addi-
tional RCTs suﬃciently powered to evaluate the
eﬀects of low-dose dexamethasone therapy on rates
of survival without BPD, as well as on other short-
and long-term outcomes, are warranted.
Recommendation. There is insuﬃcient evidence to
make a recommendation regarding treatment with
low-dose dexamethasone.
(3) Low-dose hydrocortisone therapy (1mg/kg per day)
given for the ﬁrst 2 weeks of life may increase rates of
survival without BPD, particularly for infants deliv-
ered in a setting of prenatal inﬂammation, without
adversely aﬀecting neurodevelopmental outcomes.
Clinicians should be aware of a possible increased
risk of isolated intestinal perforation associated
with early concomitant treatment with inhibitors
of prostaglandin synthesis. Further RCTs powered
to detect eﬀects on neurodevelopmental outcomes,
aimed at targeting patients who may derive most
beneﬁt and developing treatment strategies to reduce
the incidence of isolated intestinal perforation, are
warranted.
Recommendation. Early hydrocortisone treatment
may be beneﬁcial in a speciﬁc population of patients;
however, there is insuﬃcient evidence to recommend
its use for all infants at risk of BPD.
(4) Higher doses of hydrocortisone (3–6mg/kg per day)
instituted after the ﬁrst week of postnatal age have
not been shown to improve rates of survival without
BPD in any RCT. RCTs powered to assess the eﬀect
of this therapy on short- and long-term outcomes are
needed.
Recommendation. Existing data are insuﬃcient to
make a recommendation regarding treatment with
high-dose hydrocortisone.
6. Summary
BPDisthediseaseofverylowbirthweightandextremelylow
birthweightnewbornswithmultifactorialetiologyincluding
prematurity itself, ventilator-induced injury, oxygen, and
inﬂammation. BPD has long-term adverse pulmonary and
neurodevelopment outcome. Steroids usage for treatment of
BPD also has been shown to have adverse neurodevelopmen-
tal outcome. Available data are conﬂicting and inconclusive;
clinicians must use their own clinical judgment to balance
theadverseeﬀectsofBPDwiththepotentialadverseeﬀectsof
treatments for each individual patient. Very low birth weight
infants who remain on mechanical ventilation after 1 to 2
weeks of age are at very high risk of developing BPD [58].
When considering corticosteroid therapy for such an infant,
clinicians might conclude that the risks of a short course of
glucocorticoid therapy to mitigate BPD are warranted [59].
This individualized decision should be made in conjunction
with the infant’s parents.International Journal of Pediatrics 9
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